全文获取类型
收费全文 | 267篇 |
免费 | 10篇 |
国内免费 | 4篇 |
专业分类
儿科学 | 3篇 |
妇产科学 | 2篇 |
基础医学 | 15篇 |
口腔科学 | 4篇 |
临床医学 | 14篇 |
内科学 | 80篇 |
皮肤病学 | 2篇 |
神经病学 | 21篇 |
特种医学 | 1篇 |
外科学 | 36篇 |
综合类 | 2篇 |
预防医学 | 70篇 |
药学 | 16篇 |
肿瘤学 | 15篇 |
出版年
2023年 | 1篇 |
2022年 | 1篇 |
2021年 | 4篇 |
2020年 | 4篇 |
2019年 | 2篇 |
2018年 | 6篇 |
2017年 | 4篇 |
2016年 | 6篇 |
2015年 | 7篇 |
2014年 | 10篇 |
2013年 | 18篇 |
2012年 | 23篇 |
2011年 | 36篇 |
2010年 | 15篇 |
2009年 | 7篇 |
2008年 | 8篇 |
2007年 | 15篇 |
2006年 | 18篇 |
2005年 | 25篇 |
2004年 | 20篇 |
2003年 | 16篇 |
2002年 | 19篇 |
2001年 | 7篇 |
2000年 | 3篇 |
1999年 | 4篇 |
1997年 | 1篇 |
1986年 | 1篇 |
排序方式: 共有281条查询结果,搜索用时 15 毫秒
21.
Metastatic disease remains a significant contributor to morbidity and mortality in patients with breast cancer. An improved molecular and biochemical understanding of the metastatic process is expected to fuel the development of new therapeutic approaches. The suppression of tumor metastasis, despite tumor cell expression of oncogenes and metastasis-promoting events, has become a diverse and fruitful field of investigation. Although many genetic events promote metastasis, several genes show relatively reduced expression levels in metastatic tumor cells in mouse model systems and in aggressive human tumors. Re-expression of a metastasis-suppressor gene in a metastatic tumor cell line results in a significant reduction in metastatic behavior in vivo with no effect on tumorigenicity. The known metastasis-suppressor gene products nm23, KAI1, mitogen-activated protein kinase kinase 4, breast cancer metastasis suppressor-1, KiSS1, RHOGDI2, CRSP3, and vitamin D3-upregulated protein/thioredoxin interacting protein exhibit unexpected biochemical functions that have shed new light on signaling events that are important in metastasis. Most metastasis suppressors function at the translationally important stage of outgrowth of micrometastatic tumor cells at a distant site. We hypothesize that elevation of metastasis suppressor gene expression in micrometastatic tumor cells in the adjuvant high-risk population of patients with breast cancer will halt metastatic colonization and have a clinical benefit. DNA methylation inhibitors have shown limited promise in increasing metastasis-suppressor gene expression, and ligands of the nuclear hormone receptor family are currently under investigation in vitro and in vivo. Clinical testing of agents that increase metastasis-suppressor gene expression is expected to require tailored trial designs. 相似文献
22.
Gasnault J Kousignian P Kahraman M Rahoiljaon J Matheron S Delfraissy JF Taoufik Y 《Journal of neurovirology》2001,7(4):375-381
A monocenter observational study was conducted to determine the clinical and virological effects of cidofovir added to highly active anti-retroviral therapy (HAART) in AIDS-associated progressive multifocal leukoencephalopathy (PML). Exposure to other anti-viral drugs or late initiation of cidofovir were exclusion criteria. Of the 53 consecutive patients with virologically proven PML admitted at the NeuroAIDS Unit of Bicêtre Hospital between May 1996 and July 2000 and having received HAART with or without cidofovir, 46 met the inclusion criteria. Cidofovir was initiated in most cases on compassionate grounds. The 22 patients treated with HAART only (HAART group) were compared to the 24 patients treated with HAART and cidofovir (CDV group). Survival, neurological outcome assessed by the expanded disability status scale (EDSS), and monitoring of the JC virus (JCV) load in CSF were investigated prospectively. At baseline (date of initiation or intensification of HAART), both groups were similar regarding CD4 cell count, plasma HIV load, CSF JCV load, EDSS, and demographic features. Both groups had similar response to HAART in terms of plasma HIV load and CD4 cell count. At month 6, CSF-JCV load was below the detection level in 8 out of 24 (33%) patients from the CDV group and 7 out of 18 (39%) patients from the HAART group (P = 0.71). One-year cumulative probability of being alive was 62% in the CDV group and 53% in the HAART group (P = 0.72). However, an additional benefit with respect to survival was observed in patients who were given cidofovir after adjustment to the following baseline variables (CSF-JCV load, CD4 cell count, and EDSS). Despite the addition of cidofovir to HAART, no significant benefit had been observed in neurological outcome, particularly in patients with an early worsening. 相似文献
23.
24.
Georg Fuernau Karl Fengler Steffen Desch Ingo Eitel Franz-Josef Neumann Hans-Georg Olbrich Antoinette de Waha Suzanne de Waha Gert Richardt Marcus Hennersdorf Klaus Empen Rainer Hambrecht Christian Jung Michael Böhm Janine Pöss Ruth H. Strasser Steffen Schneider Taoufik Ouarrak Gerhard Schuler Karl Werdan Uwe Zeymer Holger Thiele 《Clinical research in cardiology》2016,105(12):1030-1041
25.
26.
27.
Newly established tumourigenic primary human colon cancer cell lines are sensitive to TRAIL-induced apoptosis in vitro and in vivo 总被引:2,自引:0,他引:2
Oikonomou E Kothonidis K Taoufik E Probert E Zografos G Nasioulas G Andera L Pintzas A 《British journal of cancer》2007,97(1):73-84
Most data on the therapeutic potential of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) as well as resistance to FAS ligand (FASL) in colorectal cancer have come from in vitro studies using cell lines. To gain a clearer understanding about the susceptibility of patient tumours to TRAIL and FASL, we derived primary human cancer epithelial cells from colon cancer patients. Characterisation of primary cultures PAP60 and MIH55 determined their highly proliferating advantage, transforming capability and tumorigenicity in vitro and in vivo. Although FASL treatment appeared to cause little apoptosis only in the PAP60 primary culture, increased apoptosis independent of p53 was observed in both primary PAP60 and MIH55 and control cell lines Caco-2, HT29 and DLD-1 after treatment with SuperKiller TRAIL. Expression analysis of death receptors (DR) in the original parental tumours, the primary cultures before and after engraftment as well as the mouse xenografts, revealed a significant upregulation of both DR4 and DR5, which correlated to differences in sensitivity of the cells to TRAIL-induced apoptosis. Treating patient tumour xenograft/SCID mouse models with Killer TRAIL in vivo suppressed tumour growth. This is the first demonstration of TRAIL-induced apoptosis in characterised tumorigenic primary human cultures (in vitro) and antitumour activity in xenograft models (in vivo). 相似文献
28.
29.
Kadi N Tahiri L Maziane M Mernissi FZ Harzy T 《Joint, bone, spine : revue du rhumatisme》2012,79(1):83-84
Proximal symphalangism is a rare autosomal dominant affection responsible for multiple joint ankylosis, it results from NOG gene mutation whose locus is on 17q21-22. This gene may be involved in secretory functions of glands such as ovarian function. Premature ovarian failure is idiopathic in 80% of cases but may be secondary to multiple etiologies including genetic. We report the case of a patient with proximal symphalangism and premature ovarian failure, and we discuss the possibility of genetic relationship between the two anomalies. 相似文献
30.